JNJ

Traders rotated out of high-flying semiconductor stocks and into less volatile investments. Dividend stocks can help you protect your wealth.

SpaceX has experienced high volatility since going public earlier this month. Further volatility may be just around the corner, due the company's unique staggered lock-up expiration process.

Johnson & Johnson offers a unique blend of steady growth, portfolio depth, and resilience, distinguishing it from both AI-driven and pharma peers. JNJ's diversified pharma and MedTech assets underpin robust revenue growth, with 28 platforms generating $1bn+ annually and 13 pharma brands growing double digits. I expect JNJ to deliver reliable 9% annual returns, driven by 8% EPS growth, a 2.4% dividend yield, and disciplined capital allocation.

Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week.

Our Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) 24/7 Wall St.

Bear markets typically follow periods of extreme enthusiasm.  The technology sector has been driving the market higher, and it may be time to hedge your bets a little with a stock like Johnson & Johnson.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.

Johnson & Johnson (JNJ) reached $228.39 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.